Regulation of lipid production by acetylcholine signalling in human sebaceous glands

Li, Zheng Jun; Park, Seung Bae; Sohn, Kyung Cheol; Lee, Young; Seo, Young‐Joon; Kim, Chang Deok; Kim, Youn Sung; Lee, Jeung Hoon; Im, Myung

doi:10.1016/j.jdermsci.2013.06.009

Cited by 88 publications

(95 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sebum reducing effects of botulinum toxin will probably cause lower activity of sebaceous glands (14), and the thickness of the facial pachydermia will appear to be thinner afterwards. The effects of botulinum toxin in reducing wrinkles in thinner skin will be greater than that in thicker skin according to the clinical experiences of the authors.…”

Section: Discussionmentioning

confidence: 99%

Facial Manifestations of Pachydermoperiostosis Treated with Botulinum Toxin Type-A: Report of 3 Cases

Wen

Li²,

Hamblin³

et al. 2017

Acta Derm Venerol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Facial Manifestations of Pachydermoperiostosis Treated with Botulinum Toxin Type-A: Report of 3 Cases

Wen

Li²,

Hamblin³

et al. 2017

Acta Derm Venerol

View full text Add to dashboard Cite

“…Previous studies indicated that confluent sebocytes contained more intracellular lipid droplets with differentiated sebocytes [12,13,14]. Therefore, we used pre-confluent undifferentiated sebocytes to explore the role of adiponectin when sebaceous gland activity decreased.…”

Section: Adiponectin Enhances Lipid Synthesis In Human Sebocytesmentioning

confidence: 98%

267 Adiponectin signaling regulates lipid production in human sebocytes

Lee¹,

Jung

Kim³

et al. 2017

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Adiponectin plays important roles in metabolic function, inflammation and multiple biological activities in various tissues. However, evidence for adiponectin signaling in sebaceous glands is lacking, and its role remains to be clarified. This study investigated the role of adiponectin in lipid production in sebaceous glands in an experimental study of human sebocytes. We demonstrated that human sebaceous glands in vivo and sebocytes in vitro express adiponectin receptor and that adiponectin increased cell proliferation. Moreover, based on a lipogenesis study using Oil Red O, Nile red staining and thin layer chromatography, adiponectin strongly upregulated lipid production in sebocytes. In three-dimensional culture of sebocytes, lipid synthesis was markedly enhanced in sebocytes treated with adiponectin. This study suggested that adiponectin plays a significant role in human sebaceous gland biology. Adiponectin signaling is a promising target in the clinical management of barrier disorders in which sebum production is decreased, such as in atopic dermatitis and aged skin.

show abstract

“…67 BoNT-A has been shown to decrease sebum production and reduce pore size in individuals with oily skin, probably by blocking the activity of acetylcholine in sebocytes. 68 BoNT may also exert its effects via its action on the sebaceous gland. 69,70 …”

Section: Medical Developmentsmentioning

confidence: 99%

New Uses of AbobotulinumtoxinA in Aesthetics

Schlessinger¹,

Gilbert²,

Cohen³

et al. 2017

Aesthetic Surgery Journal

View full text Add to dashboard Cite

BotulinumtoxinA (BoNT-A) is now widely established for the main approved indication of reducing glabellar lines, and is also widely used off-label to improve the appearance of wrinkles and lines in other parts of the face. The number of aesthetic procedures continues to increase as the patient population becomes more diverse, in particular with increasing numbers of people of color and men. Further developments in treatment may continue to expand the audience for BoNT-A by making procedures more comfortable and by delivering a more natural, less static appearance. These may be achieved through use of combinations of BoNT-A with other aesthetic procedures, tailoring the dose of toxin to the patient’s muscle mass or by using novel injection and application techniques. Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrophic and keloid scars and even to prevent them. Studies have been conducted with scars in various parts of the body and further research is ongoing. Dermatological and other medical uses for BoNT-A are also active areas of research. Injections of BoNT-A have been shown to reduce signs and symptoms of acne, rosacea, and psoriasis, to reduce neuromuscular pain, and to bring about significant improvements in a number of rare diseases that are caused or exacerbated by hyperhidrosis. This paper reviews these new uses for BoNT-A, looking at the rationale for their use and discussing the results of published case studies and clinical trials. These areas have shown great promise to date, but more and larger clinical studies will be required before these treatments become a clinical reality. To this end details are also provided of clinical trials currently listed in the main clinical trials database to highlight research areas of particular interest.

show abstract

Regulation of lipid production by acetylcholine signalling in human sebaceous glands

Cited by 88 publications

References 32 publications

Facial Manifestations of Pachydermoperiostosis Treated with Botulinum Toxin Type-A: Report of 3 Cases

Facial Manifestations of Pachydermoperiostosis Treated with Botulinum Toxin Type-A: Report of 3 Cases

267 Adiponectin signaling regulates lipid production in human sebocytes

New Uses of AbobotulinumtoxinA in Aesthetics

Contact Info

Product

Resources

About